May increase conc of pimozide (leading to QT prolongation & Torsades de pointes) & ergot alkaloids (may lead to ergotism). May increase plasma conc when co-administered w/ OATP1B1/3 transporter inhibitors. Potential decreased plasma conc when co-administered w/ strong & moderate inducers of transporters (eg, P-gp) &/or enzymes (eg, UGTs). Initial increased followed by clinically relevant decreased plasma conc when co-administered w/ rifampin. Increased plasma conc of amiodarone, glyburide, atorvastatin, sirolimus, tacrolimus. Decreased plasma conc by rifampin. Plasma conc may be decreased by nafcillin, carbamazepine, phenobarb, rifabutin, thioridazine, bosentan, St. John's wort, efavirenz, etravirine, nevirapine, modafinil. May have mutual decrease in plasma conc w/ phenytoin. Decreased plasma conc of voriconazole. May decrease plasma conc of warfarin, omeprazole & pantoprazole. Not recommended to be co-administered w/ pitavastatin & simvastatin; significantly increased pitavastatin or simvastatin conc (may lead to myopathy or rhabdomyolysis). May increase plasma conc of other HMG-CoA reductase inhibitors (eg, fluvastatin, lovastatin, pravastatin, rosuvastatin), CYP2C8 substrates (eg, repaglinide, rosiglitazone), CYP3A substrates (eg, alfentanil, fentanyl, midazolam, quinidine).